<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438694</url>
  </required_header>
  <id_info>
    <org_study_id>N39-2020</org_study_id>
    <nct_id>NCT04438694</nct_id>
  </id_info>
  <brief_title>Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection</brief_title>
  <acronym>CP IN COVID19</acronym>
  <official_title>Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concept of this clinical trial is built on the collection of convalescent plasma from
      individuals who had recovered from documented infection with SARS-CoV-2, to be used for
      patients with- or at high risk of progression to- severe/life-threatening clinical conditions
      due to SARS-CoV-2 infection.

      An informed consent is required to join this clinical trial; patients will be transfused with
      one or two units of ABO compatible convalescent plasma. Those patients will be followed up
      and the clinical and laboratory data will be compiled, including adverse events related to
      the administration of convalescent plasma (CP).

      Other data to be collected retrospectively will include patient demographics, acute care
      facility resource utilization (total length of stay, days in ICU, days intubated, and
      survival till discharge from an acute care facility).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be done inside Cairo university hospitals, it will involve a number of CP
      donors who were recovered from COVID-19 infection and were treated at Cairo University
      isolation hospital. The CP donation process will take place at CUH blood bank ,the number of
      the donors will be determined at the end of the study as it will vary according to the
      donation process .

      The study will also include sixty sever /life threatening COVID-19 patients admitted to Cairo
      University isolation hospital.

      The patients will be divided into 3 groups, first group will include 20 patients who will
      receive the current standard protocol alone , the second group will include 20 patients who
      will receive one dose of the Convalescent plasma plus the current standard protocol of
      treatment and third group 20 patients who will receive two dose of the Convalescent plasma 48
      hours a part plus the current standard protocol of treatment as therapeutic trial for testing
      dose effect of CP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This an experimental interventional study, phase I, open label, 3 arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hospitalization/Recovery status</measure>
    <time_frame>2-3 weeks</time_frame>
    <description>Decrease of hospital days of safety until discharge</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>STANDARD OF COARE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STANDARD CP DOSE Adm Single time</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose CP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STANDARD CP DOSE Adm TWICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of CP 48 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>Convalescent Plasma</description>
    <arm_group_label>STANDARD CP DOSE Adm Single time</arm_group_label>
    <arm_group_label>STANDARD CP DOSE Adm TWICE</arm_group_label>
    <arm_group_label>STANDARD OF COARE</arm_group_label>
    <other_name>CP Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have laboratory confirmed COVID-19 and admitted to Cairo University isolation
             hospital.

          -  Admitted to acute care facility.

          -  Must have severe or immediately life-threatening COVID-19:

        Severe disease is defined as:

          -  dyspnea,

          -  respiratory frequency ≥ 30/min,

          -  blood oxygen saturation ≤ 93%,

          -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt;300, and/or

          -  lung infiltrates &gt; 50% within 24 to 48 hours (CT finding)

        Life-threatening disease is defined as:

          -  respiratory failure,

          -  septic shock, and/or

          -  multiple organ dysfunction or failure

        Exclusion Criteria:

          -  Pregnancy

          -  Autoimmune disorder

          -  Participated in a CP trial in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nermeen ElDesouky, MD PhD</last_name>
    <phone>01006029006</phone>
    <email>nermeen.eldesoukey@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa ElShazly, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Omar Fahmy, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akram AbdelBarry, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasser Nassar, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heba Sharaf, Md PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Azza AboulEnin, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashraf ElFiky, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Nermeen El Desouky</investigator_full_name>
    <investigator_title>PROFESSOR OF CLINICAL PATHOLOGY</investigator_title>
  </responsible_party>
  <keyword>DONOR</keyword>
  <keyword>RECIPIENT</keyword>
  <keyword>CONVALESCENT PLASMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

